Catalent Inc (NYSE:CTLT) insider John R. Chiminski sold 181,458 shares of the stock in a transaction that occurred on Tuesday, December 12th. The shares were sold at an average price of $39.62, for a total value of $7,189,365.96. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Shares of Catalent Inc (CTLT) opened at $40.06 on Friday. Catalent Inc has a twelve month low of $25.51 and a twelve month high of $43.39. The company has a current ratio of 2.91, a quick ratio of 2.49 and a debt-to-equity ratio of 2.01. The firm has a market capitalization of $5,320.00, a price-to-earnings ratio of 27.65, a PEG ratio of 2.54 and a beta of 1.41.

Catalent (NYSE:CTLT) last posted its earnings results on Monday, November 6th. The company reported $0.21 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.20 by $0.01. Catalent had a return on equity of 23.97% and a net margin of 5.01%. The company had revenue of $543.90 million during the quarter, compared to the consensus estimate of $490.75 million. During the same quarter last year, the firm earned $0.16 earnings per share. The company’s revenue was up 23.0% on a year-over-year basis. research analysts forecast that Catalent Inc will post 1.46 EPS for the current fiscal year.

Institutional investors and hedge funds have recently bought and sold shares of the company. State of Wisconsin Investment Board bought a new position in shares of Catalent in the second quarter worth $3,334,000. 361 Capital LLC increased its position in shares of Catalent by 18.6% in the third quarter. 361 Capital LLC now owns 70,022 shares of the company’s stock worth $2,795,000 after purchasing an additional 10,974 shares during the period. Chicago Equity Partners LLC increased its position in shares of Catalent by 20.4% in the second quarter. Chicago Equity Partners LLC now owns 109,825 shares of the company’s stock worth $3,855,000 after purchasing an additional 18,600 shares during the period. Sei Investments Co. increased its position in shares of Catalent by 119.1% in the third quarter. Sei Investments Co. now owns 94,216 shares of the company’s stock worth $3,761,000 after purchasing an additional 51,212 shares during the period. Finally, Airain ltd bought a new position in shares of Catalent in the second quarter worth $3,524,000. 99.49% of the stock is owned by institutional investors.

CTLT has been the subject of several recent analyst reports. Zacks Investment Research downgraded Catalent from a “buy” rating to a “hold” rating in a report on Friday, September 1st. Bank of America reaffirmed a “buy” rating and set a $40.00 price target (up previously from $38.00) on shares of Catalent in a report on Tuesday, August 29th. William Blair reaffirmed an “ourperform” rating on shares of Catalent in a report on Tuesday, August 29th. ValuEngine raised Catalent from a “hold” rating to a “buy” rating in a report on Thursday, September 7th. Finally, Piper Jaffray Companies reaffirmed a “buy” rating and set a $45.00 price target on shares of Catalent in a report on Tuesday, August 29th. Four research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Catalent presently has a consensus rating of “Buy” and a consensus price target of $44.44.

TRADEMARK VIOLATION NOTICE: This piece was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another domain, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2017/12/15/john-r-chiminski-sells-181458-shares-of-catalent-inc-ctlt-stock.html.

Catalent Company Profile

Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.

Receive News & Stock Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related stocks with our FREE daily email newsletter.